期刊文献+

不同剂量阿托伐他汀对冠心病急性心梗伴心衰行PCI患者血清hs-CRP的影响 被引量:27

Effect of atorvastatin at different dosage on hs-CRP of patients with acute myocardial infarction and heart failure
在线阅读 下载PDF
导出
摘要 目的:探讨阿托伐他汀不同剂量对冠心病急性心肌梗死(AMI)伴有心力衰竭患者经皮冠状动脉介入术(PCI)前、后高敏C反应蛋白(hs-CRP)的影响。方法:选取AMI伴心衰拟行PCI患者87例,随机分为低剂量、中剂量、高剂量3组,并分别口服阿托伐他汀10、20、40 mg/d,在PCI前即刻(0 h)、术后12 h、24 h、72 h及4周(4 W)时检测血清hs-CRP水平。结果:3组术后各时间点血清hs-CRP较0 h均明显升高(P均<0.05),并随时间延长有升高趋势,4 W时趋于稳定;高剂量阿托伐他汀能更显著降低血清hs-CRP(P<0.05)。结论:高剂量阿托伐他汀可明显降低AMI伴心衰行PCI患者血清hs-CRP水平,从而减轻机体因PCI促发的炎症反应,期望降低冠脉支架术后再狭窄发生率。 Objective: To explore effect of atorvastatin at different dosage on hs-C-reactive protein(CRP) of patients with acute myocardial infarction(AMI) and heart failure after percutaneous coronary intervention(PCI).Methods: A total of 87 cases with AMI and heart failure were randomly divided into three groups: low-dosage group,middle-dosage group and high-dosage group.All patients in three groups had oral administration of atorvastatin at 10,20 and 40 mg/d,respectively.The level of hs-CRP in serum were meas the level a tendency. ured before PCI t Oh, hs-CRP w (Oh), and 12h, 24h, 72h and 4 weeks after surgery. Results ere increased significantly at other times (All P〈0.05) with The level was stable at th nificant (P〈0.05). Conclusions: tients with AMI and heart failure. e 4th week. Atorvastatin orvastatin at high dosage It can relief inflammation Compared with time-dependent at high dosage decreased hs CRP more sig can significant decrease hs-CRP level of pa reaction due to PCI and is expected to decrease incidence of restenosis.
作者 代永红
出处 《海南医学院学报》 CAS 2011年第2期203-205,共3页 Journal of Hainan Medical University
基金 海南医学院科研基金资助学报项目(0020110036)~~
关键词 阿托伐他汀 急性心肌梗死 充血性心力衰竭 经皮冠状动脉介入术 C反应蛋白 Atorvastatin; Acute myocardial infarction; Congestive heart failure; Percutaneous coronary intervention; CRP;
  • 相关文献

参考文献8

  • 1Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cell by anti- atherosclerosis drugs[J]. Circulation, 2001,103 : 2581- 2534.
  • 2Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long term mortality after non ST elevation acute coronary syndrome treated with a very early inva sive strategy in 1042 consecutive patients[J]. Circulation,2006,105:1412-1415.
  • 3Shak PK. Circulating markers of inflammation for vas cular risk prediction: are they ready for prime time? [J]. Circulation,2008. 101 : 1758-1759.
  • 4Yip HK, Wu CJ, Chang HW, et al. l.evels and values of serum high-sensitivity C reactive protein within 6 hours after the onset of acute myocardial infarction[J]. Chest,2007,126:1417-1422.
  • 5Chan DC, WattsGF, Barrett HR, et al, Effect ofator vastatin and fish oil on plasma high sensitivity C reac tive protein concentrations in individuals with visceral o besity[J]. Clinical Chemistry,2002,48(6) : 877 883.
  • 6陆建洪,沈震,汤胜军.阿托伐他汀对缺血性心肌病的心功能影响[J].实用临床医药杂志,2007,11(3):89-90. 被引量:3
  • 7陈耀强,李志梁,赵霞.PCI术对冠心病患者hs-CRP及TNFα的影响[J].实用医学杂志,2005,21(21):2430-2431. 被引量:8
  • 8问海燕,陈宏斌.强化阿托伐他汀对老年冠状动脉介入后血清MCP-1、hs-CRP和sFas因子的影响[J].细胞与分子免疫学杂志,2010,26(2):167-168. 被引量:30

二级参考文献19

共引文献36

同被引文献281

引证文献27

二级引证文献186

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部